[1] WALLACE D C. Mitochondria and cancer[J].Nat Rev Cancer, 2012, 12(10):685-698. [2] TAN A S,BATY J W,DONG L F, et al. Mitochondrial genome acquisition restores respiratory function and tumorigenic potential of cancer cells without mitochondrial DNA[J]. Cell Metab, 2015, 21(1):81-94. [3] FORMENTINI L,MARTÍNEZ-REYES I, CUEZVA J M. The mitochondrial bioenergetic capacity of carcinomas[J]. IUBMB Life, 2010, 62(7):554-560. [4] SENIOR A E. ATP synthase:motoring to the finish line[J]. Cell, 2007, 130(2):220-221. [5] GEYIK E,IGCI Y Z,PALA E, et al. Investigation of the association between ATP2B4 and ATP5B genes with colorectal cancer[J]. Gene, 2014, 540(2):178-182. [6] XU G,LI J Y. ATP5A1 and ATP5B are highly expressed in glioblastoma tumor cells and endothelial cells of microvascular proliferation[J]. J Neurooncol, 2016, 126(3):405-413. [7] SUN J,YANG Z L,MIAO X, et al. ATP5b and β2-microglobulin are predictive markers for the prognosis of patients with gallbladder cancer[J]. J Mol Histol, 2015, 46(1):57-65. [8] LU Z, SONG Q, SONG Q, et al. Preparation of monoclonal antibody against lung cancer and identification of its targeting antigen[J]. J Biomed Engineering, 2010, 27(1):147-151. [9] 刘素霞. 重组单克隆抗体生产的宿主细胞系的研究进展[J]. 科技风, 2018, 9(25):36. [10] SALTZ L. Systemic therapy for metastatic colorectal cancer[J]. J Natl Compr Canc Netw, 2013, 11(Suppl 5):649-652. [11] SALTZ L B,LENZ H J,KINDLER H L, et al. Randomized phase Ⅱ trial of cetuximab,bevacizumab and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer:the BOND-2 study[J]. J Clin Oncol, 2007, 25(29):4557-4561. [12] 邓云秋. EGFR单克隆抗体靶向药物治疗脑胶质瘤的研究进展[J]. 中国处方药, 2018, 16(8):22-23. [13] 朱慧,李春蕊. 多发性骨髓瘤的免疫治疗进展[J]. 医药导报, 2018, 37(10):1160-1165. [14] 赵源浩. 靶向抗肿瘤单克隆抗体类药物联合常规化疗方案治疗转移性结直肠癌的临床进展[J]. 中国药房, 2018, 29(14):2012-2016. [15] 刘志, 赵春清, 张彬, 等. VEGF、Bmi-1在结肠癌组织中的表达及意义[J].河北医药, 2016, 38(20):3104-3106. [16] GREENING D W,LEE S T,JI H, et al. Molecular profiling of cetuximab and bevacizumab treatment of colorectal tumoursreveals perturbations in metabolic and hypoxic response pathways[J]. Oncotarget, 2015, 6(35):38166-38180. [17] SÁNCHEZ-ARAGÓ M, CHAMORRO M, CUEZVA JM. Selection of cancer cells with repressed mitochondria triggers colon cancer progression[J]. Carcinogenesis, 2010, 31(4):567-576. [18] REN L R,ZHANG L P,HUANG S Y,et al. Effects of sialidase NEU1 siRNA on proliferation, apoptosis, and invasion in human ovarian cancer[J]. Mol Cell Biochem, 2016, 411(1/2):213-219. [19] FLIEDNER S M, YANG C,THOMPSON E, et al. Potential therapeutic target for malignant paragangliomas:ATP synthase on the surface of paraganglioma cells[J]. Am J Cancer Res, 2015, 5(4):1558-1570. [20] LI W, LI Y, LI G, et al. Ectopic expression of the ATP synthase β subunit on the membrane of PC-3M cells supports its potential role in prostate cancer metastasis[J]. Int J Oncol, 2017, 50(4):1312-1320. [21] LYNAM-LENNON N, Maher SG, Maguire A, et al. Altered mitochondrial function and energy metabolism is associated with a radioresistant phenotype in oesophageal adenocarcinoma[J]. PLoS ONE, 2014, 9(6):e100738. [22] XIAO X, YANG J, LI R, et al. Deregulation of mitochondrial ATPsyn-β in acute myeloid leukemia cells and with increased drug resistance[J]. PLoS ONE, 2013, 8(12):e83610. [23] 蒋灵旭,罗颖婉,佟红艳.急性髓系白血病靶向治疗新进展[J].中国实用内科杂志,2018,38(12):1198-1202. |